Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.
Overview
Investing in a top company can offer safety and stability, but oftentimes, the potential upside can also be limited. Take Eli Lilly (NYSE:LLY) as a prime example. It's a leader in the GLP-1 space and a top healthcare company, with a market cap of more than $1 trillion. It's generated impressive returns totaling more than 400% in five years, but with a much higher valuation, it may not perform nearly as well over the next five years.
Targeting a smaller stock instead may be a more compelling option for investors. And one that could have plenty of upside is Viking Therapeutics (NASDAQ:VKTX). It recently gave investors some terrific news related to its GLP-1 drug.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.